GlassScriptPhysician profile
Khalid Bin Ahmed Baosman
NPI 1982047932
$1,941.09
in general payments reported to CMS, 2019-2025
16 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $13.94 · 2021: $446 · 2022: $255 · 2023: $495 · 2024: $174 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $664.74 | 2019-2023 | Nuzyra |
| Melinta Therapeutics, LLC | $250.00 | 2023-2024 | Kimyrsa |
| Astrazeneca Pharmaceuticals LP | $140.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $133.29 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Penumbra, INC. | $129.06 | 2025 | Indigo System |
| Gilead Sciences, INC. | $125.00 | 2023 | Veklury |
| La Jolla Pharmaceutical Company | $116.89 | 2023 | Xerava |
| Allergan, INC. | $93.55 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $73.48 | 2023 | Epkinly, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $50.03 | 2019-2021 | |
| Atricure, INC. | $48.73 | 2024 | |
| Novartis Pharmaceuticals Corporation | $40.57 | 2021-2022 | |
| Pfizer INC. | $37.24 | 2019-2025 | |
| Abbvie INC. | $13.81 | 2025 | |
| Novo Nordisk INC | $13.65 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $10.75 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Baosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.